LivaNova price to sales ratio LIVN

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: 3.0×
10-year median: 2.8×
Against its 10-year history: 56th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.5× to 5.7×
Peer median: 2.3×

LivaNova's price to sales ratio is 3.0× as of Oct 23, 2026.

That is above its ten-year median of 2.8×, close to the middle of its last ten years.

Over that time it ranged from 1.5× in Apr 2025 to 5.7× in Aug 2018.

The median for 6 medical device stocks of a similar size is 2.3×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.0×	2.3×	3.2×
2025	2.5×	1.5×	2.6×
2024	2.0×	2.0×	2.9×
2023	2.5×	2.1×	3.1×
2022	2.9×	2.3×	4.4×
2021	4.5×	3.2×	4.7×
2020	3.4×	1.6×	3.5×
2019	3.3×	2.9×	4.5×
2018	4.0×	3.2×	5.7×
2017	3.1×	1.9×	3.5×

Against its peers

Companies in Medical - Devices nearest LivaNova's size, closest first, today.

Company	Price to sales ratio
LIVNLivaNova	3.0×
ITGRInteger	2.3×
TMDXTransMedics	3.7×
CNMDCONMED	1.1×
ZBHZimmer Biomet	2.2×
DXCMDexCom	5.9×
GEHCGE HealthCare Technologies	1.5×
Peer median	2.3×

Where LivaNova ranks

#12of 26Medical device stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on LivaNova

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.